Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol UBE2I contributors: mct/npt/pgu - updated : 08-04-2016
HGNC name ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast)
HGNC id 12485
  • conserved UBC domain of 150 AA harboring the cysteine residue required for enzyme-ubiquitin thioester formation
  • C-terminus involved in both the protein-protein interaction and its sumoylation-modifying activity provide the mechanism for regulating nuclear receptor functions
    interspecies homolog to yeast UBC9
    homolog to S.Cerevisiae Scubc9
  • ubiquitin-conjugating enzyme family
  • CATEGORY enzyme
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,nucleus,nucleoplasm,nuclear bodies,nuclear speckles
  • strikingly colocalized with SFRS2, which is a component of nuclear speckles and critical for mRNA processing
  • expressed predominantly in the nucleus of preadipocytes but shifted to cytoplasmic compartments
  • SAE1, UBE2I and PIAS1 are distributed in both nucleus and cytoplasm of ocular cell lines
  • basic FUNCTION
  • involved in ubiquitin conjugation,second step of ubiquitin-dependent proteolysis
  • SUMO-E2 enzyme, sufficient for substrate recognition and lysine modifications of SUMO targets
  • promoting nuclear accumulation and metabolic stability of tumor suppressor SMAD4
  • can function as a co-factor of PLAGL2, uncoupling from its enzymatic activity, to mediate PLAGL2 interactive surfactant protein-C promoter activity
  • essential gene which is required for cell cycle progression and is involved in the degradation of S phase and M phase cyclins
  • sufficient for substrate recognition and lysine modification of known SUMO targets
  • essential protein in mammalian cells with a predominantly nuclear localization
  • critical for mRNA processing, and having a possible function of sumoylation in gene expression
  • E2-conjugating enzyme that transfers the activated small ubiquitin-like modifier (SUMO) to protein substrates, and thus it has an important function in sumoylation-mediated cellular pathways
  • involved in protein modification through covalent attachment of small ubiquitin-like modifier and, has emerged as a key regulator of cell proliferation and differentiation
  • appears to play an important role in adipogenesis
  • negatively regulates osteoblastic differentiation induced by BMP via, at least in part, SUMOylation of SMAD4
  • UBE2I acts as a functional binding partner of FYB1 and plays a selective role in integrin-mediated T cell adhesion via modulation of RAP1A-RASSF5 membrane recruitment and RAC1 activation
  • CELLULAR PROCESS cell cycle
    nucleotide, repair
    protein, degradation
    a component
  • UBE2I associated to FHIT
  • RANBP2 forms a stable complex with SUMO-modified RANGAP1 and UBE2I at the nuclear pore complex
  • member of the surfactant protein-C promoter complex
  • IPO13ľUBE2I9 complex forms in the cytosol and translocates into the nucleus
  • non-covalent ternary complex formed by PIAS1, SUMO1, and UBE2I proteins involved in transcriptional regulation
    small molecule
  • associating with RAD51, RAD52 proteins in the double strand RAD51/RAD52 repair pathway
  • associating with UBL1 and TP53, involved in DNA recombination and essential for cell-cycle progression
  • associating with FHIT for cell-cycle control
  • interacting with ETV6 leading to sumoylation of ETV6 (TEL) by UBL (SUMO-1)
  • interacted with the DNA-binding and ligand-binding domains of ESR1
  • protein interacting with UIMC1
  • interacted with SOX4 through HMG-box domain of SOX4 and represses its transcriptional activity independent of its SUMO-1-conjugating activity
  • interacting with STAR and FOXL2 (UBE2I-mediated sumoylation at lysine 25 of FOXL2 is required for transcriptional repression of the STAR gene and may be responsible for controlling the development of ovarian follicles)
  • ZMYND11 interacts with PIAS1 (a well-characterized SUMO E3 enzyme) and UBE2I (the only SUMO E2 enzyme so far identified) through its distinct regions
  • molecular link between UBE2I and the metastasis genes such as CDC42 and CXCR4, and thus provide new insight into the mechanism by which UBE2I9 promotes tumor invasion and metastasis
  • binding of BRCA1 proteins to nuclear chaperone UE2I provides a novel mechanism for nuclear import and control of tumor growth
  • is an interaction partner of the transcription factor EGR2, a key regulator of hindbrain development
  • SETD8 interacts with the UBE2I E2 SUMO conjugating enzyme (directly binds SETD8 proximal to the catalytic SET domain)
  • RANBP2 forms a stable complex with SUMO-modified RANGAP1 and UBE2I at the nuclear pore complex
  • SKI can enhance UBE2I-mediated cellular sumoylation, possibly through direct interaction with UBE2I
  • interaction between the CANX cytoplasmic domain and UBE2I, a SUMOylation E2 ligase, which modified the calnexin cytoplasmic domain by the addition of SUMO
  • UBE2I interacted directly with FYB1 and the association was increased in response to anti-CD3 stimulation
  • cell & other
    Other autosumoylation of the mammalian E2-conjugating enzyme UBE2I at Lys14 regulates target discrimination
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in advanced melanomas
    Susceptibility to late-onset Alzheimer disease (AD)
    Variant & Polymorphism other UBE2I polymorphisms might be associated with a risk of AD
    Candidate gene
    Therapy target
    blocking expression of UBE2I sensitizes melanomas to the cytotoxic effects of chemotherapeutic drugs